Navigation Links
Genasense(R) Data in Melanoma to be Presented in Opening Session at First Worldwide Melanoma Center Meeting of the European Association of Dermato-Oncology
Date:9/5/2007

a's lead anticancer drug, is a novel targeted therapy that blocks the production of Bcl-2, a protein that appears to be a fundamental cause of cancer treatment resistance. By knocking down Bcl-2, Genasense may enhance the effectiveness of chemotherapy in patients with advanced melanoma. Genasense in melanoma has Orphan Drug designations in Australia and the U.S., along with Fast Track designation in the U.S.

In its initial Phase 3 trial, Genta performed the largest randomized controlled trial that has ever been conducted in patients with advanced melanoma. In that trial, 771 patients were randomly assigned to receive chemotherapy with DTIC alone or in combination with Genasense. A scientific article that describes efficacy and safety results from this study can be accessed at: http://www.jco.org/cgi/content/abstract/JCO.2006.06.0483v1.

In that trial, patients were prospectively stratified according to levels of a blood enzyme known as LDH. Further analysis of this study showed that maximum benefit accrued to patients whose LDH biomarker did not exceed 80% of the upper limit of normal. Efficacy results in this group of 274 patients, which are the focus of the confirmatory AGENDA trial, are displayed in the table below. (The hazard ratios indicate that the addition of Genasense to DTIC was associated with a 42% reduction in the risk of disease progression and a 36% reduction in risk of death.)

Endpoint Genasense/DTIC DTIC Hazard P

Ratio

Overall response 20.8 % 7.2 % 0.002

Durable response 10.7 % 2.4 % 0.007

Progression-free survival,

median 3.6 mos. 1.6 mos. 0.58 <0.0001

Overall survival, median 12.3 mos. 9.9 mos. 0.64 0.0009

A
'/>"/>

SOURCE Genta Incorporated
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. IDM Pharma Presents Preliminary Results from Phase II UVIDEM Melanoma Vaccine Clinical Trial
2. Synta Presents Results for STA-4783 in Metastatic Melanoma Showing Improvement in Overall Survival
3. Data Demonstrated Metastatic Melanoma Response to Investigational Immunotherapy Ipilimumab
4. Long-Term Pegylated Interferon Alfa-2b Therapy in Stage III Melanoma Demonstrated Significant and Sustained Impact on Relapse-Free Survival
5. Kosan Presents Preliminary Phase 2 Data Showing Antitumor Activity of Hsp90 Inhibitor Tanespimycin in Metastatic Melanoma at ASCO
6. SciClone and Sigma-Tau Report Thymalfasin Meets Primary Endpoint in Phase 2 Malignant Melanoma Trial
7. Inovio Biomedicals DNA Delivery Technology Shows Safety and Enhances Gene Expression & Tumor Responses in Interim Melanoma Clinical Study Results
8. Multiferon Shows Potent Activity in Preventing the Progression of Malignant Melanoma; Study to be Published
9. Phase 3 Results for Dabigatran Etexilate, an Investigational Oral Anticoagulant, Presented Today at the XXIst Congress of the International Society on Thrombosis and Haemostasis
10. Halozyme Therapeutics Enhanze Technology Large Protein Molecule Therapeutic Clinical Trial Results Presented at the 34th Annual Meeting of the Controlled Release Society
11. Positive ZIO-201 Interim Phase II Sarcoma Data Presented at European Society for Medical Oncology
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/22/2014)... -- Sanomedics International Holdings, Inc. (OTCQB: SIMH) – According ... Data Services, demand for thermometers is expected to grow ... demand for more accurate digital thermometers continues.  ... market for thermometers, and one of the companies serving ... Inc. Sanomedics International Holdings designs, develops, markets, ...
(Date:10/22/2014)... REDWOOD CITY, Calif. , Oct. 22, 2014 ... ) today announced that results from the  IAP310 ... and Pain Medicine (RAPM), a peer-reviewed journal ... placebo-controlled, Phase 3 trial evaluating the safety and ... sufentanil sublingual tablet system (SSTS), for the treatment ...
(Date:10/20/2014)...  PneumRx, Inc. ( www.pneumrx.com ), a leader in ... enrollment in their RENEW Study, nearly 3 months ahead ... IDE pivotal trial for the PneumRx RePneu Coil System, ... anticipated that the study, which began enrolling subjects in ... end of 2014 to enroll 315 patients.  Instead, enrollment ...
Breaking Medicine Technology:Sanomedics International Holdings Analyst Report: Taking Some Heat by BrokerBank Securities, Inc. 2AcelRx Announces Publication of Zalviso Phase 3 Abdominal Trial Results 2PneumRx Completes RENEW Pivotal Trial Enrollment 2PneumRx Completes RENEW Pivotal Trial Enrollment 3
... CMC Biologics, a Contract Manufacturing Organization with manufacturing ... completion of a new state-of-the-art disposable manufacturing facility at ... of a staged major expansion plan, which will add ... a growing demand for cGMP manufacture of biopharmaceuticals. ...
... Aug. 24 Kewaunee Scientific Corporation (Nasdaq: KEQU ... ended July 31, 2010. Sales for the quarter ... first quarter of the prior year. This was primarily the ... and mid-sized laboratory projects and the scheduled timing of shipments ...
Cached Medicine Technology:CMC Biologics Completes First Stage of Expansion with Addition of Single-Use Facility 2Kewaunee Scientific Reports Sales and Earnings for First Quarter 2Kewaunee Scientific Reports Sales and Earnings for First Quarter 3Kewaunee Scientific Reports Sales and Earnings for First Quarter 4
(Date:10/22/2014)... Best Cheap Hosting USA is among the most distinguished ... announced that iPower ( http://www.best-cheap-hosting-usa.com/go/iPower/ ) is the best ... world. , “iPower is one of the most reliable ... kinds of useful products for new and old clients. ... service and a number of features which will appeal ...
(Date:10/22/2014)... Prussia, PA (PRWEB) October 22, 2014 ... recognized as an industry leader with over 25 years ... winning team leader in the areas related to EDI, ... Mr. Carlson is an Editorial Advisory Board member for ... Council Educator. Blue Fin Group is a management ...
(Date:10/22/2014)... HealthDay Reporter , TUESDAY, Oct. ... men may lead to increased blood pressure, according to a ... rise in blood pressure for young adult women or for ... women drank lightly or moderately, their risk of high blood ... finding parallels studies in older adult men and women," said ...
(Date:10/20/2014)... The newly updated Worldwide Medical Market ... of facts, figures and forecasts on the global medical ... forecast categories the Worldwide Medical Market Forecasts to ... views on the worldwide medical market to reveal key ... you data for 2010-2019, covering each country market individually, ...
(Date:10/20/2014)... Women’s health specialist, Dr. Amber Murphy, MD, Ob/Gyn ... Inc., A Division of MaternOhio Clinical Associates, Inc., who ... patients annually. Dr. Murphy will provide a full range ... women’s life. She is accepting new patients at two ... , Dr. Murphy offers a wide variety of services ...
Breaking Medicine News(10 mins):Health News:Best Cheap Hosting USA Has Recently Announced The Best Cheap Web Hosting Companies In 2014 2Health News:Rich Carlson and Marc Duey to Hold Workshop at CBI’s Specialty Pharmacy and Distribution Networks Conference 2Health News:Binge Drinking May Boost Blood Pressure in Young Men 2Health News:Binge Drinking May Boost Blood Pressure in Young Men 3Health News:Binge Drinking May Boost Blood Pressure in Young Men 4Health News:Worldwide Medical Market Forecasts to 2019 a New Research Report Added to ReportsnReports.com 2Health News:Worldwide Medical Market Forecasts to 2019 a New Research Report Added to ReportsnReports.com 3Health News:Worldwide Medical Market Forecasts to 2019 a New Research Report Added to ReportsnReports.com 4Health News:OhioHealth Welcomes New Women’s Health Specialist to MaternOhio Specialists in Obstetrics & Gynecology of Columbus, Inc. 2Health News:OhioHealth Welcomes New Women’s Health Specialist to MaternOhio Specialists in Obstetrics & Gynecology of Columbus, Inc. 3
... Iraq may not show sign of problems right away, study ... 40 percent of the U.S. soldiers from the Iraq and ... disorders or psychosocial behavioral problems, a new study shows. , ... found that most mental health diagnoses were not made in ...
... , NEW YORK and LOS ANGELES, July 16 ... The Cleaner , with Benjamin Bratt starring as an ,extreme ... producer Warren Boyd. What,s encouraging about The Cleaner is ... of addictive behavior. With more than 23 million Americans misusing drugs ...
... one of many dangers for children in unattended vehicles, experts ... time of year, but especially in warm weather, don,t even ... New research from the U.S. National Highway Traffic Safety Administration ... children is hyperthermia, better known as heat stroke. , ...
... , OAKLAND, Calif., July 16 Arcadian Health announced ... to present at the BMO Capital Markets sponsored 9th Annual Focus ... at the Millennium Broadway Hotel. Arcadian is a leading provider of ... hospitals, health plans and other provider groups. , ...
... , , Archer: "We,re Determined to Make ... he Standard for Reform " , ... health care project director Diane Archer today praised the House for introducing ... that America,s Affordable Health Choices Act is designed to control costs and deliver quality ...
... Two common supplements lower body fat, build muscle in obese ... (HealthDay News) -- For certain people, dietary oil supplements could ... , Obese older women with type 2 diabetes who ... their diet either decreased their body mass index or boosted ...
Cached Medicine News:Health News:Many Veterans Need Mental Health Care 2Health News:Many Veterans Need Mental Health Care 3Health News:Many Veterans Need Mental Health Care 4Health News:Coming Clean About The Cleaner - Phoenix House's Chief Clinical Officer David Deitch on Intervention, and the Recovery Process That Follows 2Health News:Coming Clean About The Cleaner - Phoenix House's Chief Clinical Officer David Deitch on Intervention, and the Recovery Process That Follows 3Health News:Cars Are No Place for Kids to Be Alone 2Health News:Arcadian Chairman and Chief Executive Officer, Robert Fahlman, to Present at Focus on Healthcare Conference in New York City 2Health News:Dietary Oils May Help Some Fight Fat 2Health News:Dietary Oils May Help Some Fight Fat 3
0.5 mm, 1 x 2 teeth set at 45 degrees. Serrated handle with polished finish....
Serrated handle with 7 mm tying platform and polished finish. Teeth: 0.25 mm, 2 x 2 set at 45 degrees....
1 x 2 teeth and 5.5 mm tying platform. Round knurled handle with polished finish. Teeth: 0.3 mm....
6 mm tying platform. Round knurled handle with polished finish. Teeth: 0.3 mm, 1 x 2. Orientation: Left hand....
Medicine Products: